Meeting
2023 ASCO Annual Meeting
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).
Authors
Benjamin Besse
Institut Gustave Roussy, Villejuif, France
Benjamin Besse , Luis G. Paz-Ares , Solange Peters , Federico Cappuzzo , Martin Reck , Antonio Calles , Raffaele Califano , Jose Antonio Lopez-Vilariño , Susie Veramendi , Carmen Maria Kahatt , Ali Hassan Zeaiter , Jacob Sands
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05153239
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8613)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8613
Abstract #
TPS8613
Poster Bd #
233a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.
First Author: Sophie Cousin
Poster
2023 ASCO Annual Meeting
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
First Author: Luis G. Paz-Ares
Poster
2022 ASCO Annual Meeting
Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.
First Author: Alejandro Navarro
Poster
2020 ASCO Virtual Scientific Program
Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.
First Author: Santiago Ponce Aix